← All trials
NCT06414031
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 17, 2024
- Primary completion
- Nov 30, 2025
- Completion date
- Nov 30, 2025
- First posted
- May 14, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 850
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Martin Luther UniversityLead sponsor
- Martin Luther UniversitySponsor investigator
- German Federal Ministry of Education and ResearchCollaborator
- Martin Luther UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.